R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
Events Partner Content 7th Drug Formulation, Solubility & Bioavailability Latest technologies to accelerate tme-to-market.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.